Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$8.64 +0.1%	$8.09	$5.20 ▼ $10.67	$1.17B	1.15	1.35 million shs	4.36 million shs
OGN Organon & Co.	$9.87 -1.1%	$9.77	$8.01 ▼ $23.10	$2.57B	0.59	3.49 million shs	4.46 million shs
PTCT PTC Therapeutics	$49.84 +0.6%	$48.23	$29.02 ▼ $58.38	$3.95B	0.51	857,512 shs	1.39 million shs
RYTM Rhythm Pharmaceuticals	$62.73 +2.1%	$62.45	$40.46 ▼ $69.89	$3.99B	2.3	551,282 shs	857,993 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	+11.20%	+9.92%	+7.46%	+51.31%
OGN Organon & Co.	0.00%	+1.07%	+7.27%	-33.86%	-52.32%
PTCT PTC Therapeutics	0.00%	-0.72%	+2.09%	-2.20%	+62.98%
RYTM Rhythm Pharmaceuticals	0.00%	+1.19%	+2.23%	+18.43%	+52.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.5325 of 5 stars	3.5	1.0	0.0	0.0	2.1	0.8	1.9
OGN Organon & Co.	4.8394 of 5 stars	3.3	4.0	1.7	3.7	1.1	3.3	2.5
PTCT PTC Therapeutics	4.3305 of 5 stars	4.3	1.0	0.0	4.4	1.9	0.8	1.3
RYTM Rhythm Pharmaceuticals	3.8776 of 5 stars	3.5	2.0	0.0	4.3	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.10% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	82.39% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	30.42% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	23.24% Upside

Current Analyst Ratings Breakdown

Latest AUPH, RYTM, PTCT, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00
5/7/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$113.00 ➝ $112.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.31 per share	28.01	$2.68 per share	3.22
OGN Organon & Co.	$6.40B	0.40	$4.93 per share	2.00	$1.83 per share	5.39
PTCT PTC Therapeutics	$1.77B	2.23	N/A	N/A	($14.24) per share	-3.50
RYTM Rhythm Pharmaceuticals	$130.13M	30.67	N/A	N/A	$0.35 per share	179.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.86	15.43	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.43	2.64	1.03	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.66	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest AUPH, RYTM, PTCT, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.81%	N/A	2.78%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest AUPH, RYTM, PTCT, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
OGN Organon & Co.	16.49	1.67	1.15
PTCT PTC Therapeutics	N/A	3.89	3.85
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
OGN Organon & Co.	77.43%
PTCT PTC Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
OGN Organon & Co.	1.40%
PTCT PTC Therapeutics	5.50%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
OGN Organon & Co.	4,000	259.96 million	256.32 million	Not Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

AUPH, RYTM, PTCT, and OGN Headlines

Recent News About These Companies

NPSL: Bristol Rhythm fall on the road, close out season with two home games this week

1 hour ago | heraldcourier.comH

The UniverSoul Circus brings its 'Rhythm of the World' tour to National Harbor

1 hour ago | wusa9.comW

Of Wood, Worship And Wonder: Rhythm Wagholikar On The Rath Yatra Tradition

June 28 at 10:41 PM | msn.com

Rhythm & Food community BBQ

June 28 at 10:41 PM | kxnet.comK

Rhythm & Roots unveils artist schedule, puts single-day tickets on sale

June 28 at 10:41 PM | heraldcourier.comH

Rhythm & Rally offer pickleball for Neurodivergent kids

June 28 at 10:41 PM | 41nbc.com4

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Market Outperform Rating from JMP Securities

June 28 at 2:40 AM | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (RYTM) - Yahoo Finance

June 27 at 7:59 PM | finance.yahoo.com

Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic

June 27 at 4:22 PM | seekingalpha.com

Rhythm and Blues Show

June 27 at 2:56 AM | deltanews.tvD

Rhythm Pharmaceuticals Announces Late-Breaking Abstracts for ENDO 2025 Featuring Pivotal Phase 3 and Phase 2 Trial Results on Acquired Hypothalamic Obesity - Nasdaq

June 27 at 2:56 AM | nasdaq.com

Rhythm Pharmaceuticals' (RYTM) "Market Outperform" Rating Reiterated at JMP Securities

June 26, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025 | finanznachrichten.de

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025 | globenewswire.com

Avior Wealth Management LLC Invests $243,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 24, 2025 | marketbeat.com

22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A.

June 18, 2025 | marketbeat.com

SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18, 2025 | marketbeat.com

GAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18, 2025 | marketbeat.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 2,069 Shares of Stock

June 12, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Buy" from Analysts

June 12, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Buys 47,045 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, RYTM, PTCT, and OGN Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.80 +0.16 (+1.82%)

As of 04:47 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Organon & Co. NYSE:OGN

$9.87 -0.11 (-1.11%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$9.94 +0.07 (+0.71%)

As of 04:46 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

PTC Therapeutics NASDAQ:PTCT

$49.84 +0.29 (+0.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$50.06 +0.22 (+0.45%)

As of 04:05 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$62.73 +1.29 (+2.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$62.81 +0.08 (+0.13%)

As of 06/27/2025 07:50 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time